Galera Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Galera Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.05M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($18.96M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($59.08M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($62.22M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($80.53M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($74.22M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($51.93M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($23.68M) | Mar 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.54M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($20.16M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($49.26M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($51.23M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($73.37M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($70.55M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($50.69M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($24.26M) | Mar 10, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $349.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.15M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $24.12M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $31.01M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $52.42M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $54.85M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $42.33M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $18.66M | Mar 10, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.05M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($12.15M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($44.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($43.43M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($67.96M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($59.54M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($46.66M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($22.17M) | Mar 10, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $59.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $283.0K | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $457.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $633.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $347.0K | Mar 10, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $10.10M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $26.14M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $44.04M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $83.31M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $84.10M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $123.38M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $88.06M | Mar 10, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $645.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $153.77M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $157.33M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $153.22M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $141.32M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $77.98M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $53.77M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $26.97M | Mar 10, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.97M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($148.04M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | ($131.19M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | ($109.18M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($58.00M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $6.12M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $69.61M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($104.82M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | ($76.11M) | Mar 10, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $881.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $881.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $881.0K | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $881.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $881.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $881.0K | Mar 10, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($307.31M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($456.36M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($437.41M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($378.32M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($316.10M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($235.57M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($161.35M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($104.82M) | Mar 10, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.38M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $8.29M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $18.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.27M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.86M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $15.87M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $18.36M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $14.81M | Mar 10, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 75.46M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 75.46M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 54.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 28.51M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 26.46M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 24.98M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 24.81M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 300,597 | Mar 10, 2020 |